Barchart Demo Center

Overview

Stocks

Stock Screeners

ETFs

Futures

Funds

Fund Screeners

Foreign Exchange

Sectors

News

Financial Calculators

Embedded Widgets

Portfolio

Screener

JSON Feeds

Symbol Overview

United States|Canada
English|French

Evelo Biosciences Inc

(NASDAQ: EVLO)
Add to Portfolio
-0.29 (-3.55%)
as of Sep 20, 2019

Last 7.87
Change -0.29 (-3.55%)
Open 8.17
Prev. Close 8.16
Today's Range
7.87
8.38
52wk Range
4.90
15.89
Volume 242,900
Avg Volume 90,450
Sector SIC-2834 Pharmaceutical Preparations

Perfomance Comparison

Name Today 3-Month 1-Year
EVLO -3.55% -1.63% -41.66%
DJIA -0.59% -0.56% +1.04%
S&P 500 -0.49% -0.26% +2.09%

Key Statistics

Annual EPS -2.28
Dividend Yield 0.00%
P/E Ratio N/A
Market Capitalization, $K 261,610
Weighted Alpha -47.70
Standard Deviation -0.67
Profit Margin N/A
Beta -0.22

Growth Rates

YTD -39.51%
1-Year -37.88%

Opinion

Sell Hold Buy

Recent Headlines

Evelo Biosciences to Host Key Opinion Leader Symposium

GlobeNewswire via COMTEX - Fri Sep 20, 07:00AM EDT
Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing orally delivered, systemically acting biologics, today announced that it will host a key opinion leader symposium on the unmet need in mild (full story)
EVLO: 7.87 (-0.29)

Evelo Biosciences Announces the Appointment of David

GlobeNewswire via COMTEX - Tue Sep 17, 07:01AM EDT
Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing orally delivered, systemically acting biologics, announced today that David Epstein has been appointed chairman of its Board of Directors. M(full story)
EVLO: 7.87 (-0.29)

Evelo Biosciences to Present at the Morgan Stanley

GlobeNewswire via COMTEX - Wed Sep 04, 07:27PM EDT
Evelo Biosciences, Inc. (Nasdaq:EVLO), a biotechnology company developing oral biologics that act on cells in the small intestine with systemic therapeutic effects, today announced that management will participate in a fireside ch(full story)
EVLO: 7.87 (-0.29), MS: 43.67 (-0.35)

Evelo Biosciences Reports Positive EDP1815 Interim

GlobeNewswire via COMTEX - Tue Aug 06, 07:05AM EDT
-EDP1815 was Well Tolerated with No Overall Difference Reported from Placebo-(full story)
EVLO: 7.87 (-0.29)

Evelo Biosciences Announces Positive Interim Phase 1b

GlobeNewswire via COMTEX - Tue Aug 06, 07:04AM EDT
-EDP1815 and EDP1066 were Well Tolerated with No Overall Difference Reported from Placebo-(full story)
EVLO: 7.87 (-0.29)